About TreeFrog Therapeutics
TreeFrog Therapeutics is a company based in Talence (France) founded in 2018 by Maxime Feyeux and Kevin Alessandri.. TreeFrog Therapeutics has raised $84.25 million across 8 funding rounds from investors including European Investment Bank, Bpifrance and European Union. TreeFrog Therapeutics operates in a competitive market with competitors including Merck, Roivant Sciences, Gilead, Lilly and Vertex Pharmaceuticals, among others.
- Headquarter Talence, France
- Founders Maxime Feyeux, Kevin Alessandri
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$84.25 M (USD)
in 8 rounds
-
Latest Funding Round
$34.17 M (USD), Debt – Conventional
May 27, 2025
-
Investors
European Investment Bank
& 10 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Funding Insights of TreeFrog Therapeutics
TreeFrog Therapeutics has successfully raised a total of $84.25M across 8 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $34.17 million completed in May 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 8
- Last Round Debt – Conventional — $34.2M
-
First Round
First Round
(10 Jan 2019)
- Investors Count 11
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2025 | Amount | Debt – Conventional - TreeFrog Therapeutics | Valuation |
investors |
|
| Oct, 2021 | Amount | Grant - TreeFrog Therapeutics | Valuation |
investors |
|
| Sep, 2021 | Amount | Series B - TreeFrog Therapeutics | Valuation | XAnge , Leonard Green and Partners |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in TreeFrog Therapeutics
TreeFrog Therapeutics has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include European Investment Bank, Bpifrance and European Union. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Founded Year | Domain | Location | |
|
Venture capital fund focused on tech companies
|
Founded Year | Domain | Location | |
|
Recapitalizations are targeted through private equity investments by the firm.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by TreeFrog Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - TreeFrog Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Treefrog Therapeutics Comparisons
Competitors of TreeFrog Therapeutics
TreeFrog Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Merck, Roivant Sciences, Gilead, Lilly and Vertex Pharmaceuticals, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Pharmaceutical products are manufactured and marketed worldwide.
|
|
| domain | founded_year | HQ Location |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others
|
|
| domain | founded_year | HQ Location |
Traditional pharmaceutical medicines are developed for multiple health fields.
|
|
| domain | founded_year | HQ Location |
Developer of drugs for the treatment of multiple disorders
|
|
| domain | founded_year | HQ Location |
Biopharmaceutical research and drug development are conducted globally by AbbVie.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Treefrog Therapeutics
Frequently Asked Questions about TreeFrog Therapeutics
When was TreeFrog Therapeutics founded?
TreeFrog Therapeutics was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Where is TreeFrog Therapeutics located?
TreeFrog Therapeutics is headquartered in Talence, France. It is registered at Talence, Nouvelle-aquitaine, France.
Who is the current CEO of TreeFrog Therapeutics?
Maxime Feyeux is the current CEO of TreeFrog Therapeutics. They have also founded this company.
Is TreeFrog Therapeutics a funded company?
TreeFrog Therapeutics is a funded company, having raised a total of $84.25M across 8 funding rounds to date. The company's 1st funding round was a Series B of $75.58M, raised on Jan 10, 2019.
What does TreeFrog Therapeutics do?
TreeFrog Therapeutics is developing stem cells and organoids using proprietary technology to enable the development of cell therapies. It enables the younger cells to mitigate mutational risks. They have developed organoids from pluripotent stem cells.
Who are the top competitors of TreeFrog Therapeutics?
TreeFrog Therapeutics's top competitors include Merck, Roivant Sciences and AbbVie.
Who are TreeFrog Therapeutics's investors?
TreeFrog Therapeutics has 11 investors. Key investors include European Investment Bank, Bpifrance, European Union, EIC Fund, and XAnge.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.